
Idexx Laboratories guidance
$690.24−1.49%Close 17 Nov 2026 · Market value $54.38B
In its results release of 2 Nov 2026 (Q3 FY2026), Idexx Laboratories gave 4 forecasts in figures, among them revenue growth of +10.1% to +10.8% for FY2026.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q3 FY2026 results, 2 Nov 2026
| Measure | Period | Guidance | As stated |
|---|
| Revenue growth · Raised | FY2026 | +10.1% to +10.8% | ▪ Outlook for 2026 reported revenue growth raised to 10.1% - 10.8%, and CAG Diagnostics recurring revenue reported growth raised to 11.0% - 11.7%, with projected 2026 organic revenue growth of 9.3% - 10.0% and CAG Diagnostics recurring revenue organic growth of 10.3% - 11.0%. |
|---|
| Organic revenue growth · Raised | FY2026 | +9.3% to +10% | The Company is increasing its outlook for organic revenue growth to 9.3% - 10.0%, an increase of 0.6% at midpoint, reflecting operational performance. |
|---|
| EPS · Raised | FY2026 | $14.96 to $15.16 | ▪ Raises 2026 EPS outlook to $14.96 - $15.16, reflecting a $0.25 increase compared to prior guidance midpoint, led by a raised revenue outlook while supporting acquisition impacts. |
|---|
| Operating margin · Lowered | FY2026 | 32.1% to 32.3% | The Company lowered its full year reported operating margin outlook to 32.1% - 32.3%, bringing the projected full year operating profit margin expansion to 50 - 70 basis points as reported and on a comparable basis |
|---|
Source: the company's earnings release.
Guidance against results above 1 · within 1 · below 0
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Revenue | FY2026 | $4.63B to $4.72B | Given once | — | To come |
|---|
| Revenue growth | FY2026 | +10.1% to +10.8% | Raised once | — | To come |
|---|
| Organic revenue growth | FY2026 | +9.3% to +10% | Raised twice | — | To come |
|---|
| EPS | FY2026 | $14.96 to $15.16 | Raised 3 times | — | To come |
|---|
| Operating margin | FY2026 | 32.1% to 32.3% | Raised once, lowered once | — | To come |
|---|
| Net income | FY2026 | About $1.09B | Given once | — | To come |
|---|
| Revenue | FY2025 | $4.05B to $4.17B | Given once | $4.30B | Above the range |
|---|
| Revenue growth | FY2025 | +9.6% to +10.3% | Raised twice | +10.42% | Above the range |
|---|
| Operating margin | FY2025 | 31.6% to 31.8% | Raised twice | 31.6% | Within the range |
|---|
IDXX in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.